|Articles|May 3, 2003
Several studies to provide new information, data about olopatadine
Four studies about olopatadine hydrochloride ophthalmic solution 0.1%(Patanol, Alcon Laboratories) and olopatadine hydrochloride ophthalmic solution0.2% (Patanol once-a-day) will be presented at ARVO, Alcon Laboratoriesannounced.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
Noninvasive LED light therapy shows long-term safety in early cataract clinical follow-up
3
IGS 2026: The expanding role of artificial intelligence in ophthalmology
4
The Residency Report: PreserFlo microshunt vs trabeculectomy—five-year trial insights
5
























